Cesar Santa-Maria is an Oncology physician affiliated with Sidney Kimmel Comprehensive Cancer Center. OpenAlex indexes 47 publications with 479 citations (h-index 10); ClinicalTrials.gov lists 4 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1650 Orleans St # 155
Baltimore, MD 212870013
Telephone
410-955-8489Registry record last updated 2 Nov 2017.
Clinical trials
4 registered studies on ClinicalTrials.gov matched to this name. Itemized trial rows, roles and sponsors are part of the full profile. Why? →
Industry payments
3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year20251 payment
- Eli Lilly and CompanyProgram year20241 payment
- AstraZeneca Pharmaceuticals LPProgram year20243 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
90.6%Aromatase Inhibitor76.9%Anastrozole72%Letrozole16%Exemestane12%Part D<11 patientsKinase inhibitor13.7%Ibrance100%Part D<11 patientsNervous system
9.4%Opioid Agonist9.4%Oxycodone Hcl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2019–2023 per NIH RePORTER. The latest:
- Immunophenotypic biomarkers to predict response and optimize immunotherapy-based combinations in breast cancer
Johns Hopkins University
FY2023$266,518K08CA237863 - Immunophenotypic biomarkers to predict response and optimize immunotherapy-based combinations in breast cancer
Johns Hopkins University
FY2022$266,518K08CA237863 - Immunophenotypic biomarkers to predict response and optimize immunotherapy-based combinations in breast cancer
Johns Hopkins University
FY2021$265,878K08CA237863
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Prognostic value of visually and computationally assessed tumor-infiltrating lymphocytes in early-stage triple-negative breast cancer (TBCRC-030)
JNCI Journal of the National Cancer Institute
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Donald Small, MD
Sidney Kimmel Comprehensive Cancer Center
Amy Dezern, MD
Sidney Kimmel Comprehensive Cancer Center
Javier Meade, MD
Sidney Kimmel Comprehensive Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”